Management of epilepsy in the elderly by Poza, Juan José
© 2007 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2007:3(6) 723–728 723
REVIEW
Management of epilepsy in the elderly
Juan José Poza
Department of Neurology, Hospital 
Donostia, San Sebastián, Spain
Correspondence: Juan José Poza
Department of Neurology, Hospital 
Donostia, San Sebastián, Spain
Email jjpoza@chdo.osakidetza.net
Abstract: Epilepsy among the elderly is a frequently occurring pathology, differing in etiology, 
clinical presentation and prognosis from those of young people. In addition, beyond a certain age, 
physiological modiﬁ  cations are produced in the metabolism which alter the pharmacokinetics of 
antiepileptic drugs (AEDs), increasing the risk of pharmacological interactions, already greater 
in these patients due to the frequency of poly-pharmacy. Furthermore, elderly patients are par-
ticularly sensitive to certain secondary effects of AEDs, as for example, cognitive disturbances, 
osteoporosis or weight increase. Given that the efﬁ  cacy of the major AEDs is a priori quite 
similar, and that the epilepsies occurring in this age-group generally have a good prognosis, the 
selection of an AED will depend more upon its pharmacokinetics and ability to induce certain 
secondary effects than on its efﬁ  cacy. In this respect, levetiracetam and pregabalin, followed by 
oxcarbazepine and lamotrigine have the most favorable pharmocokinetical proﬁ  le. Moreover, 
on the whole these drugs have very few cognitive effects, do not induce osteoporosis and, with 
the exception of pregabalin, do not affect weight, making them the ﬁ  rst selection for use in the 
treatment of epilepsy in the elderly.
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Introduction
Epilepsy is particularly common in the over 60s. A number of epidemiological studies 
carried out around the world have shown that the prevalence of epilepsy rises rapidly 
above this age, even increasing beyond the other prevalence peak which appears in 
infancy. On the one hand, we have those patients whose epilepsy started at whatever 
age and who are now over 60 year-old, and on the other hand those in whom it started 
after this age, the latter representing 25% of the new cases of epilepsy (Sander and 
Shoevon 1996). The incidence of epilepsies in the over 60s is double the ﬁ  gure for 
those aged between 40 and 59 years old and follows a lineal growth reaching a ﬁ  gure 
of 140/100,000 for the over 80s, three times the ﬁ  gure for those in the 60–69 year-old 
age group (Loiseau et al 1990; Tallis et al 1991; Hauser 1992; Hauser et al 1993). 
Thus, epilepsy together with cerebrovascular pathology and dementias is one of the 
most common neurological pathologies in old age. Moreover, as will be seen below, 
both cerebrovascular pathology and dementias may be a cause of epilepsy. Given 
the tendency towards an ageing population in the West, an increase in the number of 
epileptic patients, particularly in this segment of the population, can be expected.
In spite of the fact that more and more often, the epileptic patients encountered in 
the surgery are over 60 years old, this age group is rarely represented in the clinical 
trials which have led to the approval of the different antiepileptic drugs (AEDs). The 
high co-morbidity, the frequency of polypharmacy, the increased risk of secondary 
effects and of mortality due to intercurrent causes in these patients are, among others, 
the reasons for their almost systematic exclusion from clinical trials. Therefore, given 
the lack of evidence based on clinical trials, we shall try to determine the most appro-
priate antiepileptic drugs for these patients according to the characteristics of their 
epilepsy, the modiﬁ  cations in the metabolic capacity of the drugs which arise with age, Neuropsychiatric Disease and Treatment 2007:3(6) 724
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the possibility of secondary effects of special relevance to the 
elderly and the characteristics of the different drugs.
Characteristics of epilepsy
in the elderly
In elderly patients, the critical phenomenology presents 
peculiarities which may make diagnosis more difﬁ  cult. For 
example, automatisms and auras are unusual in the elderly 
and often the crises present themselves as episodes of 
confusion or syncopal events. Therefore, in almost half of 
the elderly patients who are ﬁ  nally diagnosed with epilepsy, 
epilepsy is not the initial suspected diagnosis (Ramsay et al 
2004). Furthermore, the appearance of an epileptic status as 
a form of presentation of the epilepsy is also more common 
among the elderly (Pryor et al 2002).
It should be remembered that the elderly are more at risk 
of presenting reactive crises. The metabolic disorders which 
may provoke a crisis, including hypo- or hyperglycemia, 
uremia, hyponatremia or hypocalcaemia, are more common 
among the elderly. In addition, this section of the population 
tends to use drugs more frequently, including drugs poten-
tially capable of inducing an epileptic crisis, as are some 
antidepressants, neuroleptics and certain antibiotics.
Furthermore, the incidence of epilepsy is particularly 
high among the over 60s. However, this increase in the 
incident rate only corresponds to certain types of epilepsy. 
Almost no idiopathic epilepsies start in this age group. In any 
case, we may encounter patients with idiopathic epilepsies 
which started at much earlier ages and who have reached 
old age. Therefore, the possibility of a generalized epilepsy 
commencing in old age is remote, and given an patient aged 
over 60 who has developed epilepsy we should consider a 
focal epilepsy even when there is no clear focal start to the 
crises (Hiyoshi and Yagi 2000).
Practically two thirds of epilepsies which develop at this age 
are symptomatic, and the other third are cryptogenic. The most 
common cause of epilepsy among the over 60s is the cerebral-
vascular pathology, related to almost 50% of epilepsies among 
the elderly (Asconape and Penry 1991). Moreover, epilepsy 
may be the ﬁ  rst sign of an underlying vascular pathology which 
has not yet surfaced. Thus, the risk of epilepsy in hypertensive 
patients is ﬁ  ve times higher than in those who are not hyperten-
sive, probably in relation to a pathology of small blood vessels 
causing irritating symptoms before provoking an ictus (Ng et al 
1993). Cleary et al monitored a cohort of 4,709 patients with 
cryptogenic epilepsy which started at over 60 years old, and 
found that the relative risk of suffering an ictus in these patients 
compared with controls from the same population was 2.89, 
suggesting that in many of these patients there was an alteration 
to the cerebral blood ﬂ  ow which manifested itself ﬁ  rst as an 
epilepsy and then as an ictus (Cleary et al 2004).
Other frequently related causes of epilepsy in the elderly 
are brain tumors, cranial trauma and dementia.
The fact that we encounter symptomatic epilepsies condi-
tions the therapeutic attitude, as the risk of recurrence is very 
high (Bergey 2004), over 90%, and therefore starting treat-
ment after the ﬁ  rst crisis can be considered. In the majority of 
cases, good control of these epilepsies can be expected, but 
treatment will be indeﬁ  nite, and the suspension of treatment 
even after several years without a crisis can not be consid-
ered, as recurrence is almost certain. However this should 
be assessed for each particular case, as it will largely depend 
upon the risks that the patient and the doctor are willing to 
assume (Serrano Castro, Ramos Lizana et al 2005).
Modiﬁ  cations of the metabolism
in the elderly
The physiology of elderly patients presents alterations which 
modify the pharmacokinetics of AEDs, making patients 
more susceptible to secondary effects. Firstly, there is an 
atrophy of the gastric mucosa and a reduction in the intestinal 
motility, which may modify the absorption of AEDs making it 
irregular. In addition, there is a reduction in total body water, 
leading to a modiﬁ  cation of the volume of distribution of the 
drugs and their half life, which may on occasions have signiﬁ  -
cant consequences. Thus, the half life of Diazepam goes from 
20 hours in young people to 80 hours in those individuals aged 
over 80, with the resulting risk of a build-up of the drug.
The bonding of drugs to plasmatic proteins is also 
reduced. As a result, the free fraction of drugs which bond 
well to proteins, such as valproic acid, phenitoin or tiagabine 
may increase by as much as 60%, bringing with this the risk 
of secondary effects due to intoxication (Serrano Castro, 
Casado-Chocan et al 2005).
Finally, the capacity to eliminate drugs is also lower in 
the elderly than in young people. The hepatic metabolism 
is much slower, which may lead to a build-up of drugs 
with intense hepatic metabolism, such as carbamazepine, 
phenitoin or lamotrigine. Moreover, these patients will have 
a higher sensitivity to phenomenons of hepatic induction 
or inhibition, given that their hepatic reserve is reduced. In 
addition, glomerular ﬁ  ltration is also reduced, which must 
be remembered when prescribing renally eliminated drugs 
such as levetiracetam, gabapentin or pregabalin.
An added problem is that the elderly often take multiple 
medications, increasing the risk of interactions and the Neuropsychiatric Disease and Treatment 2007:3(6) 725
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possibility of secondary effects. In this respect, the lower the 
bonding to proteins and the lower the hepatic metabolism of 
a drug, the easier it will be to use and the lower the risk of 
interaction with other possible concomitant drugs.
Secondary effects of special 
relevance in the elderly
In general, elderly patients are more sensitive to the sec-
ondary effects of drugs, even at reduced doses. In addition, 
certain secondary effects frequently related to AEDs are of 
special relevance to the elderly.
Due to the inhibiting action on the central nervous system, 
many AEDs may cause cognitive disturbances. Elderly 
patients often present a reduction in their cerebral reserve 
capacity, making them particularly sensitive to this secondary 
effect. The possibility of inducing cognitive disturbances is 
very high with drugs such as phenobarbital, primadone, or the 
benzodiazepines, and is more moderate with phenitoin and 
topiramate. The last in the list often causes a characteristic 
difﬁ  culty in ﬁ  nding words. Drugs less frequently causing 
cognitive disturbances, and which are therefore safer for use 
by this segment of the population include oxcarbazepine, 
levetiracetam, gabapentin and lamotrigine.
Osteoporosis is a common disorder among the over 60s, 
particularly among women, and may be the cause of signiﬁ  -
cant disability due to chronic pain and a predisposition to 
fractures. Various AEDs may induce osteoporosis, emphasiz-
ing a risk which is already high merely as a result of ageing. 
Some, such as phenobarbital, phenitoin or carbamazepine, do 
so by interfering with the metabolism as vitamin D. Valproate 
can also induce osteoporosis by activating the osteoblasts 
which destroy bone tissue. The risk of complications due to 
osteoporosis is multiplied in an elderly patient if we add in 
an AED capable of inducing osteoporosis. Therefore, the risk 
of hip fractures in women over 65 is doubled when taking 
one of these drugs (Ensrud et al 2004). As such, a priori, we 
should avoid the use of osteoporosis inducing drugs in this 
segment of the population.
The possibility of various AEDs causing an increase in 
weight is well known. In general, we tend to consider this sec-
ondary effect when treating young patients, especially women, 
based on the assumption that these patients may be most con-
cerned about their ﬁ  gure. However, it is extremely important 
to consider the possibility of causing an increase in weight 
in elderly patients, not for aesthetic reasons but for reasons 
of health. An increase in weight increases the risk of type II 
diabetes, cardiovascular mortality and osteoarticular problems 
in a population where the risk is already higher. Moreover, an 
increase in weight leads to clumsiness in a population which 
tends to be clumsy, and increases the risk of falls in a population 
with an increased risk of osteoporosis, and therefore, greater risk 
of fractures. The ADFs most frequently associated to weight 
increase include Valproate (more than half the patients), car-
bamazepine (approximately a quarter of patients), gabapentin 
(15%–20%) and pregabalin (14%) (De Toledo et al 1997; 
Easter et al 1997; Biton 2003; Arroyo et al 2004). Topiramate 
may induce weight loss, which can be useful for overweight 
patients, but in other cases this effect may also be harmful and 
lead to malnutrition (Ben-Menachem et al 2003). Therefore, 
the most recommended drugs for this segment of the popula-
tion are those which do not tend to modify weight, including 
lamotrigine, levetiracetam and oxcarbazepine (Devinsky et al 
2000; Gidal, Sheth, Magnus et al 2003).
First choice AEDs for the elderly
From the above, we can deduce that we are faced with a 
population which will frequently present symptomatic focal 
epilepsies, for which a good response to medical treatment 
can be expected, even at lower dosages (Kwan and Brodie 
2001). The majority of AEDs available have demonstrated a 
similar efﬁ  cacy for treating this type of crisis (Mattson et al 
1985, 1992; Brodie et al 1999, 2002). Therefore, the choice 
of drug will fundamentally depend upon its pharmacoki-
netic proﬁ  le and the likelihood of causing secondary effects 
(Sánchez-Alvarez et al 2005) which, as we have seen, have 
particular repercussions among the elderly. Therefore we 
have analyzed the AEDs from this perspective.
Phenobarbital is a powerful antiepileptic, but its signiﬁ  -
cant cognitive effects, the possibility of inducing osteoporosis 
and possible pharmacological interactions rule it out for the 
treatment of epilepsies developing for the ﬁ  rst time among 
this group of patients.
Phenytoin is probably the most widely used drug among 
the elderly due to the possibility of a rapid titration and 
intravenous administration. However, the complexity of its 
pharmacokinetics, the possibility of interaction with other 
drugs, of inducing osteoporosis and its cognitive effects make 
it unadvisable (Birnbaum et al 2003).
Valproic acid is an antiepileptic with a broad spectrum, 
being very efﬁ  cient for both focal and generalized epilepsies, 
although we are principally concerned with the former among 
this population. It can be administered intravenously, enabling 
rapid titration, the treatment of status epileptics and can be 
prescribed without problem where the patient is required 
to follow a strict diet due to an intercurrent disease. The 
pharmacokinetics present certain problems, including its high Neuropsychiatric Disease and Treatment 2007:3(6) 726
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bonding to proteins and its capacity for hepatic inhibition, 
which may provoke pharmacological interactions. But the 
main problem lies in the frequency with which it causes 
weight gain, which, as we have seen, is of particular signiﬁ  -
cance to health among these patients. Other secondary effects 
of signiﬁ  cance among elderly patients include osteoporosis 
and tremor, and even Parkinson’s, in a population particu-
larly exposed to suffering from osteoporosis and tremors or 
Parkinson’s due to their age. Thrombopenia is a secondary 
effect which also appears more often among the elderly.
Carbamazepine is a powerful antiepileptic, with mini-
mum cognitive effects. Its main disadvantage is its hepatic 
capacity, making the risk of interaction with other drugs 
high, of particular signiﬁ  cance in a population where poly-
pharmacy is common. In addition it may induce osteoporosis 
and weight gain. Another two side effects to consider due to 
their higher frequency among the elderly are hyponatremia 
and alterations to the heart conduction system, which may 
cause confused or syncopal episodes respectively.
The problems presented by carbamazepine have largely 
been resolved with oxcarbazepine, whose capacity for 
hepatic induction and alterations to the heart conduction 
system are lower than its predecessor. However, it induces 
hyponatremia more frequently than carbamazepine does 
(Kutluay et al 2003).
Topiramate is a powerful antiepileptic but the frequency 
with which it causes cognitive disorders, especially nam-
ing defects makes it unadvisable as a ﬁ  rst choice for this 
population. Other secondary effects to consider given 
their possible gravity, although uncommon, include renal 
lithiasis and metabolic acidosis. Finally, the frequency of 
secondary effects requires a very slow titration of the drug, 
implying a long lapse in time until the patient is protected 
(Reife et al 2000).
Lamotrigine is a powerful antiepileptic without cogni-
tive effects, with linear kinetics, making it highly suitable 
for this population. From a pharmacokinetics perspective, 
the main disadvantage is its hepatic metabolism, which 
may be induced by other drugs, with a signiﬁ  cant reduction 
in plasmatic levels (Anderson et al 2002). On the contrary, 
valproic acid signiﬁ  cantly raises its levels and may double 
its half life (Gidal, Sheth, Parnell et al 2003). In addition it is 
a slight hepatic inducer. Moreover, the possibility of serious 
allergic reactions makes very slow titration necessary, taking 
several weeks for an efﬁ  cient dose to be reached. This time 
period is usually lower among elderly patients, as, in general, 
lower doses are required to control their epilepsy.
Tiagabine is a GABA-ergic drug with little antiepileptic 
power, requiring administration in three doses, and which 
often induces signiﬁ  cant somnolence, and therefore it is not 
recommendable for this population.
Gabapentin has a most favorable pharmacokinetical 
proﬁ  le, but its low antiepileptic activity makes it unadvis-
able. Its successor, pregabalin, has the same pharmacokinetic 
proﬁ  le, with the advantage that its antiepileptic power is 
similar to that of other greater AEDs (Gil-Nagel and Gomez 
Alonso 2005). Treatment can be started immediately with 
an efﬁ  cient dosage. The main disadvantages are its capacity 
to induce somnolence and weight gain (French et al 2003; 
Brodie 2004).
Finally, levetiracetam is a powerful antiepileptic with a 
highly favorable pharmacokinetic proﬁ  le, as it does not bond 
with proteins, nor does it metabolize in the liver and neither 
induces nor is induced. It titrates rapidly, and therefore from the 
start of treatment the patient has an efﬁ  cient dosage. The only 
disadvantage is its possibility of provoking slight irritability or 
psychiatric alterations in under 7% of elderly patients, usually 
in patients with prior psychomotor retardation (Ferrendelli et al 
2003; Morrell et al 2003; White et al 2003).
Table 1 summarizes the main advantages and disadvan-
tages of each of the AEDs.
Table 2 Secondary effects of special relevance in the elderly
Secondary effect  AEDs which may cause this effect
Cognitive disorder  PB
 PRM
 BDZ
 PHT
 TPM
Osteoporosis PB
 PHT
 CBZ
 VPA
Weight gain  VPA
 CBZ
 GBP
 PGB
Table 1 Pharmacokinetical modiﬁ  cations in the elderly
Alteration Cause
Reduced absorption  Atrophy of gastric mucosa
  Reduction in intestinal motility
Alteration in the volume  Reduction in total body water
of distribution  Reduction in bonding with proteins
Reduced elimination  Slowing down of hepatic metabolism
  Reduction of glomerular ﬁ  ltration
Pharmacokinetic competition  PolypharmacyNeuropsychiatric Disease and Treatment 2007:3(6) 727
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Table 3 Advantages and disadvantages of each AED
AED Advantage  Disadvantage
Phenobarbital  Powerful antiepileptic  Marked cognitive effects Osteoporosis
  Possibility of parenteral   Many pharmacological interactions
 administration
Phenytoin  Powerful antiepileptic  Absorption affected by food or antacids
  Possibility of parenteral   High bonding to proteins (80%–95%)
  administration  Complex, non linear kinetics
  Rapid titration  Enzymatic inducer. Inducible
  Does not affect weight  Osteoporosis
Valproic acid  Powerful antiepileptic  High bonding to proteins (80%–95%)
  Possibility of parenteral   Enzymatic inhibitor
  administration  Weight gain (50%)
  Minimum cognitive effects  Osteoporosis
   Tremor
   Thrombopenia
Carbamazepine  Powerful antiepileptic  High bonding to proteins (80%)
  Minimum cognitive effects  Hepatic metabolism
   Enzymatic  inducer.  Auto-induction
   Osteoporosis
   Weight  gain
   Hyponatremia
    Alterations to heart conduction system
   Slow  titration
   Allergic  reaction
Oxcarbazepine  Powerful antiepileptic  Slight hepatic inducer
  Linear kinetics  Bonds to proteins (67%)
  No cognitive effects  Hyponatremia
  Does not affect weight  Alteration to heart conduction system 
Topiramate  Powerful antiepileptic  Cognitive disorder
  Does not bond to proteins  Slight hepatic inducer Inducible
   Renal  lithiasis
   Metabolic  acidosis
   Slow  titration
Lamotrigine  Powerful antiepileptic  Hepatic metabolism
  Linear kinetics  Slight hepatic inducer Very inducible
  No cognitive effects  Bonds to proteins (55%–60%)
  Does not affect weight  Allergic reactions
   Slow  titration
Tiagabin   Weak  antiepileptic
   Three  doses
    High bonding to proteins (96%)
    Hepatic metabolism Inducible
   Somnolence 
Gabapentin  Rapid titration  Weak antiepileptic
  No hepatic metabolism  Three doses
  Does not bond to proteins  Saturable absorption
  No interactions  Weight gain
Pregabalin Powerful  antiepileptic Somnolence 
  Rapid titration  Weight gain
  Rapid absorption not saturable
  No hepatic metabolism
  Does not bond to proteins
 No  interactions
Levetiracetam Powerful  antiepileptic  Uncommon irritability and psychiatric disorders (7%)
 Rapid  titration
  No hepatic metabolism
  Does not bond to proteins
 No  interactions
  No cognitive alterationNeuropsychiatric Disease and Treatment 2007:3(6) 728
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In view of these characteristics, we could say that, for a 
similar a priori efﬁ  cacy, the drugs with the most favorable 
pharmacokinetic proﬁ  le are levetiracetam and pregabalin, 
followed by oxcarbazepine and lamotrigine, whose hepatic 
metabolism and bonding to proteins slightly increases the 
risk of drug interactions. Moreover, these drugs have few 
cognitive effects, do not cause osteoporosis and, except for 
pregabalin, do not affect bodyweight, making them particu-
larly attractive for treating epilepsies in the elderly.
Conclusions
Epilepsy is a common disorder among the elderly. The majority 
of epileptic patients are over 60 years old. These patients usually 
have partial symptomatic crises, which tend to reoccur, but which 
respond well to antiepileptic treatment. Given that a priori the 
efﬁ  cacy of all the major AEDs is similar in the treatment of partial 
symptomatic crises, the choice of AED for use in this popula-
tion will depend upon the pharmacokinetic properties and side 
effects. In this respect, the AEDs with a more favorable proﬁ  le for 
starting antiepileptic treatment in elderly patients include leveti-
racetam, pregabalin, lamotrigine and oxcarbazepine.
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